
24/08/2025
💊 Buprenorphine Transdermal Patch in Pain Management
🔹 Introduction
• Semi-synthetic opioid derived from thebaine
• In clinical use for over 30 years
• Acts as a non-selective mixed agonist–antagonist opioid receptor modulator
• Unique pharmacodynamic profile – allows for potent analgesia with fewer side effects
o partial agonist with a very high binding affinity for the µ-opioid receptor,
o antagonist for the δ- and κ-opioid receptors,
o agonist for the opioid receptor-like 1 receptor
• Available as transdermal patches (5, 10 & 20 mcg/hr)
• 25–100 times more potent than morphine
________________________________________
🔹 Advantages of Buprenorphine Transdermal System (TDS)
✨ Sustained Pain Relief
✨ Fewer Side Effects
• Ceiling effect on respiratory depression & euphoria
• Lower addiction potential, less constipation
• No effect on sphincter of Oddi
• Minimal impact on hypothalamic–pituitary–adrenal axis → less risk of hypogonadism
✨ Convenience & Compliance- Once-weekly, non-invasive, reliable
✨ Metabolic Benefits
• Avoids first-pass metabolism
• Safe in elderly & patients with renal/hepatic impairment (no dose adjustments required)
________________________________________
🔹 Practical Aspects for Healthcare Professionals
Indications:
• Opioid-responsive pain not controlled by non-opioid analgesics
• Effective in both nociceptive and neuropathic pain
Dosage & Administration:
• Opioid-naïve: Start with 5 mcg/hr patch
• Converting from other opioids: Discontinue all other around-the-clock opioids. Buprenorphine has the potential to precipitate withdrawal, so caution is needed.
o Prior Total Daily Dose of Opioid < 30 mg of Oral Morphine Equivalents - initiate treatment with buprenorphine patch 5 mcg/hour
o Prior Total Daily Dose of Opioid Between 30 mg - 80 mg of Oral Morphine Equivalents: start with 10 mcg/hour buprenorphine patch.
o Prior Total Daily Dose of Opioid Greater than 80 mg of Oral Morphine Equivalents per Day: buprenorphine patch 20 mcg/hour may not provide adequate analgesia for patients requiring greater than 80 mg/day oral morphine equivalents. Consider use of alternate analgesics.
Titration & Maintenance:
• Minimum titration interval: 72 hrs
• Max dose: 20 mcg/hr (due to QTc risk)
Discontinuation:
• Do not stop abruptly → taper gradually every 7 days
Application:
• Apply to non-irritated, intact skin (upper arm, chest, upper back, or side of chest)
________________________________________
🔹 Contraindications & Precautions
❌ Severe respiratory depression
❌ Severe bronchial asthma (unmonitored setting)
❌ GI obstruction
❌ Severe hepatic failure
❌ Long QT syndrome, certain antiarrhythmics
⚠️ Caution with:
• Benzodiazepines
• CYP3A4 inhibitors
• Serotonergic drugs
• Avoid with mixed agonist/antagonist analgesics (may reduce effect or precipitate withdrawal)
________________________________________
✅ Conclusion
The buprenorphine transdermal patch is a valuable and safe option for managing chronic pain. With its unique pharmacological profile, favorable side-effect spectrum, and convenient once-weekly application, it is particularly suitable for:
• Elderly patients
• Renal or hepatic impairment
• Patients requiring long-term opioid therapy